Halbgebauer et al. (2016), through a case-control study of 100 PD patients and 120 controls, demonstrated that both α-synuclein and NfL showed strong diagnostic potential, supporting their inclusion in PD biomarker panels. The gene discussed is NEFL; the disease is Parkinson disease.